查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030280

血漿分離市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球血漿分餾市場預計將從 2025 年的 268.1 億美元成長到 2031 年的 390.1 億美元，複合年成長率為 6.45%。

這個複雜過程將凝血因子、免疫球蛋白和白蛋白等治療性蛋白質成分從人類血漿中分離出來。推動市場成長的根本因素是血友病、神經系統疾病和免疫系統疾病的盛行率不斷上升，以及依賴先進血漿衍生治療方法的老年人口不斷增加。此外，人們對罕見疾病的認知不斷提高以及診斷工具的改進也顯著推動了對這些關鍵醫療服務的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 268.1億美元
市場規模：2031年 390.1億美元
複合年成長率：2026-2031年 6.45%
成長最快的細分市場 白蛋白
最大的市場 北美洲

根據義大利國家血液中心的數據，預計到2025年，義大利將採集919.7噸血漿，顯示這種原料的供應量將持續成長。然而，從血漿採集到分離的整個過程成本高昂，是全球市場擴張的主要障礙。這些高成本對全球血漿衍生藥品的可負擔性和可及性產生了負面影響，嚴重阻礙了其進一步的市場滲透。

市場促進因素

全球血漿分餾市場的主要驅動力是多個治療領域對免疫球蛋白日益成長的需求。這些蛋白質對於治療多種疾病至關重要，包括某些神經系統疾病、自體免疫疾病和原發性免疫力缺乏。這種持續的需求得益於能夠快速檢測這些疾病的診斷工具的改進，以及不斷擴大的治療環境對免疫球蛋白療法有效性的認可。例如，根據CSL於2025年8月發布的2025年年度報告，CSL Behring當年的免疫球蛋白銷售額達到60.64億美元，實現了顯著的同比成長。這些發展凸顯了這些血漿衍生療法在滿足全球關鍵醫療需求方面發揮的關鍵作用。

血漿採集網路的持續擴張是另一個大成長要素，因為這對於確保分離製程所需原料的可靠且不斷成長的供應至關重要。新採集點和對現有設施進行策略性升級，可直接增加血漿供應，從而加速重要血漿衍生藥物的生產。例如，Fierce Pharma在2025年9月報告稱，Kedrion Biopharma計劃在美國新增40多個血漿採集點，並投資超過2.6億美元用於基礎設施擴建。這項舉措清楚地展現了該產業積極主動加強供應鏈的策略。此外，大量資金正湧入整個市場；OctaPharma於2026年2月發布的2025年度報告強調，該公司在2025年投資超過4.4億歐元，以加強其產品線並支持未來的業務擴張。這些努力共同提升了該行業滿足全球患者需求的能力。

市場挑戰

整個血漿採集和分離流程的高成本是全球血漿分餾市場擴張的主要障礙。這些高成本直接影響血漿衍生藥品的最終零售價格。因此，免疫球蛋白和白蛋白等重要治療藥物的可負擔性和供應量在全球範圍內仍然有限，尤其是在預算緊張的醫療保健系統中。這種情況直接阻礙了這些救命產品的廣泛市場滲透。

這些高成本主要源自於供應鏈中大規模的基礎設施和特定的營運要求。例如，喬治城大學血液與血漿研究小組指出，到2025年，美國將有1,247個血漿採集中心。營運和維護如此龐大的網路，加上嚴格的監管、龐大的能源消耗和複雜的血漿分離方法，都導致了持續的高昂成本。這些經濟壓力最終會轉嫁到最終產品，造成治療費用過高。因此，患者獲得治療的機會有限，世界許多地區的市場成長也受到阻礙。

市場趨勢

該行業的一個顯著趨勢是創新和高度專業化的血漿衍生治療方法的興起。這大大拓展了血漿分餾的應用範圍，使其遠超過傳統產品。這項進展包括開發新的蛋白質成分，以及改進現有治療方法，透過提升作用機制和療效，治療更廣泛、更複雜的疾病。為了滿足尚未滿足的醫療需求並拓展產品線，各機構正大幅增加研發投入。例如，OctaPharma於2026年2月發布的2025年度報告詳細披露了其1.17億歐元的研發投資，凸顯了該行業致力於推動創新和推出先進血漿衍生療法的決心。這項策略重點將催生新的治療類別，並擴大整體市場規模。

另一個重要趨勢是先進分離純化技術的整合，這些技術從根本上改變了血漿分餾的安全性和生產效率。這些技術升級可望提高血漿蛋白產量，提升最終產品的純度，並降低生產成本。這些突破性進展對於提高生產擴充性和確保安全、高品質的血漿衍生藥物的穩定供應至關重要。根據 Fierce Pharma 2026 年 3 月報道，CSL 已在其位於坎卡基的工廠啟動了一項價值 15 億美元的設備升級項目，以實施「Horizo​​n 2」生產流程。此先進技術旨在從標準血漿批次中提取更多免疫球蛋白。這項投資表明，市場正在追求卓越的技術和工藝效率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血漿分離市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品成分（白蛋白、免疫球蛋白、凝血因子、蛋白酶抑制劑、其他）
    • 依應用領域（神經學、血液學、腫瘤學、免疫學等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美血漿分離市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲血漿分離市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區血漿分離市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲血漿分離市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲血漿分離市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球血漿分離市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Grifols SA
  • Octapharma AG
  • Intas Pharmaceuticals Ltd
  • LFB SA
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Biotest AG
  • Kedrion SpA
  • Bio Products Laboratory Ltd.
  • Bharat Serums and Vaccines Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5091

The Global Plasma Fractionation Market is anticipated to expand from USD 26.81 Billion in 2025 to USD 39.01 Billion by 2031, reflecting a compound annual growth rate of 6.45%. This complex procedure involves isolating therapeutic protein elements, such as coagulation factors, immunoglobulins, and albumin, from human blood plasma. The fundamental catalyst for this market growth is the rising incidence of hemophilia, neurological ailments, and immunological disorders, coupled with an expanding elderly demographic that relies on advanced therapies derived from plasma. Additionally, heightened awareness and enhanced diagnostic tools for rare illnesses are substantially boosting the need for these vital medical treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 26.81 Billion
Market Size 2031USD 39.01 Billion
CAGR 2026-20316.45%
Fastest Growing SegmentAlbumin
Largest MarketNorth America

Data from the National Blood Centre reveals that Italy collected 919.7 tonnes of plasma in 2025, demonstrating a continuous rise in the availability of this raw material. Nevertheless, the heavy expenses tied to the complete plasma collection and fractionation cycle pose a major obstacle to worldwide market expansion. These high costs negatively affect the global affordability and availability of plasma-based medicines, creating a substantial hurdle to deeper market penetration.

Market Driver

A primary catalyst for the worldwide plasma fractionation market is the escalating need for immunoglobulins in multiple therapeutic fields. These proteins are vital for managing a variety of illnesses, such as specific neurological conditions, autoimmune diseases, and primary immunodeficiencies. This continuous demand is propelled by better diagnostic tools that enable the prompt detection of these ailments, combined with a broadening therapeutic environment that acknowledges the effectiveness of immunoglobulin treatments. To illustrate, CSL's 2025 Annual Report, released in August 2025, indicated that CSL Behring achieved $6.064 billion in immunoglobulin revenue for that year, marking a significant year-over-year growth. Such progress highlights the crucial function these plasma-based therapies serve in meeting critical medical demands around the world.

The ongoing enlargement of plasma collection networks serves as another major growth driver, as it is essential for guaranteeing a reliable and growing source of raw materials for the fractionation process. Establishing new collection sites and strategically upgrading current facilities directly boost plasma availability, which in turn facilitates the increased manufacturing of crucial plasma-derived medicines. As an example, Fierce Pharma reported in September 2025 that Kedrion Biopharma intends to channel more than $260 million into broadening its United States infrastructure by adding upwards of 40 new plasma collection facilities. This dedication illustrates the sector's proactive strategy for enhancing supply chains. Additionally, the broader market draws considerable funding, highlighted by Octapharma's 2025 Annual Report from February 2026, noting that the enterprise invested in excess of €440 million throughout 2025 to fortify its product lineup and back upcoming expansion. Together, these initiatives enhance the industry's ability to fulfill the needs of patients globally.

Market Challenge

The steep expenses linked to the entire plasma collection and fractionation workflow constitute a major hurdle for the expansion of the Global Plasma Fractionation Market. These high costs directly dictate the ultimate retail price of plasma-derived medicines. As a result, the global affordability and availability of these critical treatments, such as immunoglobulins and albumin, remain restricted, especially within budget-constrained healthcare systems. This dynamic directly curtails the widespread market adoption of these life-saving products.

These elevated costs are largely driven by the massive infrastructure and specific operational demands built into the supply chain. To provide context, the Georgetown Blood and Plasma Research Group noted that the United States featured 1,247 plasma collection facilities in 2025. Operating and staffing this vast network, alongside the highly regulated, energy-demanding, and complex fractionation methods, lead to significant ongoing expenses. These economic pressures are ultimately transferred to the end product, creating exorbitant treatment prices that limit patient accessibility and obstruct market growth in multiple regions worldwide.

Market Trends

A prominent trend in the industry is the rise of innovative and highly specialized plasma-derived treatments, which broadens the applications of plasma fractionation well past conventional offerings. This progression entails creating fresh protein fractions or adapting current therapies to treat a wider array of intricate health conditions with precise mechanisms or improved effectiveness. To address unfulfilled medical requirements and broaden their offerings, organizations are pouring more funds into research and development. For example, Octapharma's 2025 Annual Report, issued in February 2026, detailed a €117 million investment in research and development, emphasizing the sector's dedication to cultivating innovation and introducing advanced plasma-based therapeutics. This strategic emphasis establishes novel treatment classifications and widens the overall market scope.

Another key trend is the integration of sophisticated separation and purification technologies, which is fundamentally transforming the safety and productivity of plasma fractionation. These technical upgrades facilitate increased plasma protein yields, enhance the purity of the final goods, and have the potential to lower production expenses. Such breakthroughs are essential for improving manufacturing scalability and guaranteeing a steady supply of secure, premium plasma-derived medicines. As highlighted by Fierce Pharma in March 2026, CSL launched a $1.5 billion upgrade at its Kankakee plant to incorporate its Horizon 2 production method, an advanced technique created to extract larger volumes of immunoglobulin from a standard plasma batch. This financial commitment highlights the market's pursuit of technological excellence and streamlined processing.

Key Market Players

  • Grifols S.A.
  • Octapharma AG
  • Intas Pharmaceuticals Ltd
  • LFB S.A.
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Biotest AG
  • Kedrion S.p.A
  • Bio Products Laboratory Ltd.
  • Bharat Serums and Vaccines Limited

Report Scope

In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasma Fractionation Market, By Product

  • Albumin
  • Immunoglobulins
  • Coagulation Factors
  • Protease Inhibitors
  • Others

Plasma Fractionation Market, By Application

  • Neurology
  • Hematology
  • Oncology
  • Immunology
  • Others

Plasma Fractionation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.

Available Customizations:

Global Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasma Fractionation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
    • 5.2.2. By Application (Neurology, Hematology, Oncology, Immunology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Plasma Fractionation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Plasma Fractionation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Plasma Fractionation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Plasma Fractionation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Plasma Fractionation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Plasma Fractionation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Plasma Fractionation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Plasma Fractionation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Plasma Fractionation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Plasma Fractionation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Plasma Fractionation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Plasma Fractionation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Plasma Fractionation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Plasma Fractionation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Plasma Fractionation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Plasma Fractionation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Plasma Fractionation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Plasma Fractionation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Plasma Fractionation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Plasma Fractionation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Plasma Fractionation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Plasma Fractionation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Plasma Fractionation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Plasma Fractionation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Plasma Fractionation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Grifols S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Octapharma AG
  • 15.3. Intas Pharmaceuticals Ltd
  • 15.4. LFB S.A.
  • 15.5. Takeda Pharmaceutical Company Limited
  • 15.6. CSL Limited
  • 15.7. Biotest AG
  • 15.8. Kedrion S.p.A
  • 15.9. Bio Products Laboratory Ltd.
  • 15.10. Bharat Serums and Vaccines Limited

16. Strategic Recommendations

17. About Us & Disclaimer